Unione Europea - italiano - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenti antineoplastici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Unione Europea - italiano - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidina - leucemia, mieloide, acuta - agenti antineoplastici - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Unione Europea - italiano - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - agenti antineoplastici - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - agenti antineoplastici - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - nivolumabum - concentrato per soluzione per infusione - nivolumabum 120 mg, natrii citras dihydricus, natrii chloridum, mannitolum, acidum penteticum, polysorbatum 80, acidum hydrochloridum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 12 ml corresp. natrium 30 mg. - onkologikum - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - relatlimabum, nivolumabum - concentrato per soluzione per infusione - relatlimabum 80 mg, nivolumabum 240 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, acidum penteticum, aqua ad iniectabile ad solutionem pro 20 ml. - fortgeschrittenes melanom - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - mavacamtenum - capsule rigide - mavacamtenum 2.5 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (nigrum), e 172 (rubrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 0.525 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - mavacamtenum - capsule rigide - mavacamtenum 5 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 1.05 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - mavacamtenum - capsule rigide - mavacamtenum 10 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (rubrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 0.84 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - mavacamtenum - capsule rigide - mavacamtenum 15 mg, silica colloidalis hydrica, mannitolum, hypromellosum, carmellosum natricum conexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (nigrum), drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172 (nigrum), ammoniae solutio concentrata, pro capsula corresp. natrium 1.26 mg. - symptomatische obstruktive hypertrophe kardiomyopathie - synthetika